RVMD Q2 2022 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+4.8% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$62M-681.1% margin

Net Income

-$61M-671.6% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

+20.3%

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$58M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$633M

Total Liabilities

$134M

Stockholders' Equity

$499M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$9M	+4.8%
Gross Profit	$9M	$9M	+4.8%
Operating Income	-$62M	-$45M	-39.4%
Net Income	-$61M	-$44M	-38.2%

Revenue Segments

Collaboration Revenue Member

$9M100%